Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients
作者:Yan Huang, Qinyi Gan, Rongtao Lai, Weijing Wang, Simin Guo, Zi-Ke Sheng, Lu Chen, Qing Guo, Wei Cai, Hui Wang, Gangde Zhao, Zhujun Cao, Qing Xie · 发表于:Frontiers in Cellular and Infection Microbiology · 年份:2022 · DOI:10.3389/fcimb.2021.733348 · 被引用次数:22 · 研究领域:Liver Disease Diagnosis and Treatment、Hepatitis C virus research、Alcohol Consumption and Health Effects
Backgrounds and Purpose Concurrent non-alcoholic fatty liver disease (NAFLD) in chronic hepatitis B (CHB) patients is a frequent and increasingly concerning problem because of the NAFLD pandemic. Admittedly, NAFLD can progress to non-alcoholic steatohepatitis (NASH) and severe fibrosis. Direct evidence of the fibrotic effect of NAFLD or NASH in chronic hepatitis B virus (HBV) infection remains lacking. We aimed to reveal the influence of concurrent histologically proven fatty liver diseases in fibrogenesis with chronic HBV infection. Methods We performed a retrospective cross-sectional study on a liver biopsy population of CHB patients without excessive alcohol intake to evaluate the prevalence of concurrent histologically proven NAFLD or NASH according to the fatty liver inhibition of progression (FLIP) algorithm and its association with the liver fibrosis stage. Results Among 1,081 CHB patients, concurrent NAFLD was found in 404 patients (37.4%), among whom 24.0% (97/404) have NASH. The presence of NASH was an independent predictor of significant fibrosis (odds ratio (OR), 2.53; 95% CI, 1.52–4.21; p < 0.001) and severe fibrosis (OR, 1.83; 95% CI, 1.09–3.09; p = 0.023) in all patients, as well as in patients with normal alanine aminotransferase (ALT) (predicting significant fibrosis, OR, 2.86, 95% CI, 1.34–6.10; p = 0.007). The presence of lobular inflammation ( p < 0.001) or presence of cytological ballooning ( p < 0.001), rather than presence of steato...